|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-3-24
|
|
pubmed:abstractText |
Both hyper- and hypokalemia increase cardiovascular risk. Modest hyperkalemia is common with angiotensin-converting enzyme inhibition. We studied post-hoc the association of an initial, on-treatment serum potassium measurement with subsequent cardiovascular outcomes over 4.5 years in 9297 individuals at high cardiovascular risk, randomized to an ACE inhibitor or to placebo.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0301-0430
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
63
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
181-7
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15786818-Aged,
pubmed-meshheading:15786818-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:15786818-Cardiovascular Diseases,
pubmed-meshheading:15786818-Female,
pubmed-meshheading:15786818-Humans,
pubmed-meshheading:15786818-Hyperkalemia,
pubmed-meshheading:15786818-Hypokalemia,
pubmed-meshheading:15786818-Male,
pubmed-meshheading:15786818-Middle Aged,
pubmed-meshheading:15786818-Potassium,
pubmed-meshheading:15786818-Ramipril,
pubmed-meshheading:15786818-Risk Factors,
pubmed-meshheading:15786818-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study.
|
|
pubmed:affiliation |
Department of Nephrology, Schwabing General Hospital, Ludwig Maximilians University, Munich, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
